# TOXICOLOGICAL PROFILE FOR 2,3-BENZOFURAN

Prepared by:

Life Systems, Inc. Under Subcontract to:

Clement International Corporation Under Contract No. 205-88-0608

Prepared for:

Agency for Toxic Substances and Disease Registry U.S. Public Health Service

September 1992

### DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

#### FOREWORD

The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) extended and amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances which are most commonly found at facilities on the CERCLA National Priorities List and which pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The lists of the 250 most significant hazardous substances were published in the <u>Federal Register</u> on April 17, 1987; on October 20, 1988; on October 26, 1989; and on October 17, 1990. A revised list of 275 substances was published on October 17, 1991.

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the lists. Each profile must include the following content:

(A) An examination, summary, and interpretation of available toxicological information and epidemiological evaluations on the hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure which present a significant risk to human health of acute, subacute, and chronic health effects.

(C) Where appropriate, an identification of toxicological testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the <u>Federal Register</u> on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile is intended to characterize succinctly the toxicological and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. Other pertinent literature is also presented but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

#### Foreword

Each toxicological profile begins with a public health statement, which describes in nontechnical language a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health will be identified by ATSDR, the National Toxicology Program (NTP) of the Public Health Service, and EPA. The focus of the profiles is on health and toxicological information; therefore, we have included this information in the beginning of the document.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

This profile reflects our assessment of all relevant toxicological testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control, the NTP, and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

William L. Roper

William L. Roper, M.D., M.P.H. Administrator Agency for Toxic Substances and Disease Registry

## CONTENTS

FORE	WORI	)	• • • •			• •	•••	• •	•	•••	•	•	•	•	•	•	•	•	iii
LIST	C OF	FIGURES					• • •	• •	•	•••	•		•	•		•	•	•	ix
LIST	OF	TABLES				• •			•	•••	•	•	•	•	•	•	•	•	xi
1.	PUBI	LIC HEAL	TH STATEM	IENT								•	•	•					1
	1.1	WHAT I	S 2,3-BEN	ZOFURAN	? .									•					1
	1.2	HOW MI	GHT I BE	EXPOSED	TO 2	2,3-B	ENZOF	URAN	?										1
	1.3	HOW CA	N 2,3-BEN	ZOFURAN	ENT	ER AN	D LEA	VE M	ΥB	ODY	?			•	•				2
	1.4	HOW CA	N 2,3-BEN	ZOFURAN	AFF	ECT M	Y HEA	LTH?						•					2
	1.5	TS THE	RE A MEDI	CAL TES	TTO	DETE	PMINE	UHE	THF	RT	H۵	VF							
		BEEN E	XPOSED TO	) 2.3-BE	NZOFI	JRAN?						_							2
	1.6	WHAT R	XPOSED TO ECOMMENDA	TIONS H	AS TH	HE FE	DERAL	GOV	ERN	MEN	ΓŇ	íAD	E	•	•	•	-	•	-
		TO PRO	TECT HUMA	N HEALT	'H? .														3
	1.7	WHERE	CAN I GET	MORET	NFORM	 1ATTO	 V?	•••	•	•••	•	•	•	•	•	•	•	•	3
	±.,	WILLIUM					•••••	•••	•	•••	•	•	• •	•	•	•	•	•	
2.	HEAT	ידא הדיד	CTS																5
۷.	2.1	TNTDOD		• • • •	• •	•••	• • •	•••	•	• •	•	•	•	•	•	•	•	•	5
	2.2	DISCUS	UCTION . SION OF H	 IEATTU E	 	 rc pv	 דווסמ		. Ev		י. ז סוו	•	•	•	•	•	•	•	5
	2.2		JUN OF H	CALIN C	FFECI		ROUI	E OF	ĽΛ	ruai	URE	ف	•	•	•	•	•	•	6
		2.2.1		on Expo	sure	• •	• • •	• •	•	•••	•	•	•	•	•	•	•	·	
			2.2.1.1																6 6
			2.2.1.2																
			2.2.1.3																6
			2.2.1.4		ogica		tects	• •	•	•••	•	•	•	•	•	٠	•	•	6
			2.2.1.5																6
			2.2.1.6																6
			2.2.1.7	Genoto															6
			2.2.1.8	Cancer															6
		2.2.2	Oral Exp																6
			2.2.2.1						•		•			•		•			14
			2.2.2.2		ic Ef	Efects	s		•				•	•	•	•			15
			2.2.2.3	Immuno	logic	cal E:	ffect	s.					•						18
			2.2.2.4	Neurol	ogica	al Eff	fects								•				18
			2.2.2.5																18
			2.2.2.6	Reprod	uctiv	ve Efi	fects												19
			2.2.2.7		xic E	Effect	ts.												19
			2.2.2.8	Cancer															19
		2.2.3	Dermal E	xposure												;			19
			2.2.3.1	Death					÷		·				·			Ż	19
			2.2.3.2	System															19
			2.2.3.3	Immuno															20
			2.2.3.4	Neurol															20
			2.2.3.5	Develo															20
			2.2.3.6	Reprod															20
			2.2.3.7	Genoto															20
			2.2.3.7																
	2.3	TOVICO	Z.Z.S.8 KINETICS	Cancer															20
	د. ۷																		20
		2.3.1	Absorpti	.on	• •								•		•	•			20

vi

		2.3.1.1 Inhalation Exposure	20 20
		2.3.1.3 Dermal Exposure	21
		2.3.2 Distribution	21
		2.3.2.1 Inhalation Exposure	21
		•	21
			21
		2.3.2.3 Dermal Exposure	21
		2.3.3 Metabolism	21
		2.3.4 Excretion	
		2.3.4.1 Inhalation Exposure	21
		2.3.4.2 Oral Exposure	21
	<b>.</b> .	2.3.4.3 Dermal Exposure	21
		RELEVANCE TO PUBLIC HEALTH	21
	2.5	BIOMARKERS OF EXPOSURE AND EFFECT	25
		2.5.1 Biomarkers Used to Identify and/or Quantify Exposure	07
		to 2,3-Benzofuran	27
		2.5.2 Biomarkers Used to Characterize Effects Caused	0.0
		by 2,3-Benzofuran	28
	2.6	INTERACTIONS WITH OTHER CHEMICALS	28
	2.7	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	28
	2.8	MITIGATION OF EFFECTS	28
	2.9	ADEQUACY OF THE DATABASE	29
		2.9.1 Existing Information on Health Effects of	
		2,3-Benzofuran	30
		2.9.2 Data Needs	30
		2.9.3 On-going Studies	35
3.	CHEM	ICAL AND PHYSICAL INFORMATION	37
	3.1	CHEMICAL IDENTITY	37
	3.2	PHYSICAL AND CHEMICAL PROPERTIES	37
4.	PROD	UCTION, IMPORT, USE, AND DISPOSAL	41
	4.1	PRODUCTION	41
	4.2	IMPORT/EXPORT	41
	4.3	USE	41
	4.4	DISPOSAL	42
			42
5.	POTE	NTIAL FOR HUMAN EXPOSURE	43
5.	5 1		43
	5.2	RELEASES TO THE ENVIRONMENT	43
		5.2.1 Air	43
		5.2.2 Water	43
		5.2.3 Soil	45
	5.3	ENVIRONMENTAL FATE	45
		5.3.1 Transport and Partitioning	45
		5.3.2 Transformation and Degradation	46
		5.3.2.1 Air	46
		5.3.2.2 Water	46
		5.3.2.3 Soil	46
	5.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	46
	2.4		-
		5.4.1 Air	46
		5.4.2 Water	46
		5.4.3 Soil	47

	5.5 5.6 5.7	5.4.4 Other Environmental Media47GENERAL POPULATION AND OCCUPATIONAL EXPOSURE47POPULATIONS WITH POTENTIALLY HIGH EXPOSURES48ADEQUACY OF THE DATABASE485.7.1 Data Needs485.7.2 On-going Studies50
6.	6.1 6.2	TICAL METHODS51BIOLOGICAL MATERIALS51ENVIRONMENTAL SAMPLES53ADEQUACY OF THE DATABASE536.3.1 Data Needs536.3.2 On-going Studies56
7.	REGU	ATIONS AND ADVISORIES
8.	REFEI	ENCES
9.	GLOS	ARY
APP	ENDIC	S
	A.	USER'S GUIDE
·	B.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS
	C.	PEER REVIEW

## LIST OF FIGURES

2-1	Levels of Significant Exposure to 2,3-Benzofuran - Oral	•	•	•	•	•	•	11
2-2	Existing Information on Health Effects of 2,3-Benzofuran	•	•	•	•		•	31
5-1	Frequency of NPL Sites with 2,3-Benzofuran Contamination		•		•			44

/

· •

## LIST OF TABLES

2-1	Levels of Significant Exposure to 2,3-Benzofuran - Oral	7
2 - 2	Genotoxicity of 2,3-Benzofuran <u>In Vitro</u>	26
3-1	Chemical Identity of 2,3-Benzofuran	38
3-2	Physical and Chemical Properties of 2,3-Benzofuran	39
6-1	Analytical Methods for Determining 2,3-Benzofuran in Biological Materials	52
6-2	Analytical Methods for Determining 2,3-Benzofuran in Environmental Samples	54
7-1	Regulations and Guidelines Applicable to 2,3-Benzofuran	58